The Safety Evaluation of TAE for Ruptured Hepatocellular Carcinoma and Ablation-Related Hemorrhage, and the Clinical Significance of Postoperative Liver Function Changes.

Abstract

Objective: This study evaluates the safety of transarterial embolization (TAE) for treating ruptured hemorrhage in liver cancer and postablation bleeding, comparing postoperative liver function indicators such as alanine aminotransferase (ALT), total bilirubin (TBIL), and prothrombin time percentage (PT%).

Methods: A retrospective analysis was conducted on liver function changes before and after surgery in 3 patient groups: ruptured hemorrhage, postablation bleeding, and a control group (routine TAE). The safety of TAE was assessed by comparing preoperative and postoperative levels of ALT, TBIL, and PT%, using ROC curve analysis to evaluate predictive values for liver injury.

Results: All patients successfully underwent surgery, with a 100% hemostasis success rate. The 30-day survival rates were 90.91% for the rupture group and 100% for the ablation group, while 1-year survival rates were 45.45% and 85.19%, respectively. Significant pre- and postoperative changes in ALT and TBIL were found within groups, but no significant differences were observed compared to the control group. ROC analysis showed strong predictive values for ALT and TBIL increases regarding liver injury.

Conclusion: TAE is a safe and effective treatment for ruptured hemorrhage and post-ablation bleeding in liver cancer. Postoperative liver function changes in these groups are comparable to controls. Monitoring ALT and TBIL is crucial for early detection of liver injury, informing timely interventions. These findings enhance TAE protocols and liver protection strategies, improving outcomes for liver cancer patients.